Skip to content

SIGYN THERAPEUTICS, INC.

SIGY

CIK 0001642159

← back to feed
Revenue (TTM)
$101.02K
+405.6% YoY Q3 Nov 2025
Net Income (TTM)
−$3.9M
+19.4% YoY Q3 Nov 2025
EPS Diluted (TTM)
−$2.62
+33.4% YoY Q3 Nov 2025
Gross Margin
73.4%
Q3 Nov 2025
Operating Margin
-2,188.3%
Q3 Nov 2025
Net Margin
-3,855.9%
Q3 Nov 2025
Free Cash Flow (TTM)
−$1.55M
Q3 Nov 2025
Cash
$85.57K
Q3 Nov 2025
Total Debt
$3.85M
Q3 Nov 2025
Shares Outstanding
1.61M sh
Q3 Nov 2025

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings